Conclusion
Acute lung injury is a common problem in COVID-19 patients and results
in significant morbidity and mortality. However, increasing clinical and
epidemiological evidence suggests that COVID-19 infection is associated
with myocardial injury and arrhythmic complications.
Even though the prevalence of COVID-19 arrhythmogenic has yet not been
reported, close cardiovascular surveillance is advisable, particularly
in patients with more severe presentation and in those with increased
baseline risk due to previous cardiac comorbidities. Since many
medications are being used empirically to treat the infection and/or
symptoms, there is a need to increase awareness to possible drug
interactions and close monitoring in atrioventricular conduction and QT
interval.